社区
首页
集团介绍
社区
资讯
行情
学堂
TigerGPT
登录
注册
lawgbk
IP属地：未知
+关注
帖子 · 282
帖子 · 282
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
lawgbk
lawgbk
·
2021-05-11
Comment pls
Palantir Technologies Could Have an Unpleasant Surprise on This Week’s Earnings
PLTR stock is struggling into a suddenly key earnings report.There are two reasons why first-quarter
Palantir Technologies Could Have an Unpleasant Surprise on This Week’s Earnings
看
1,562
回复
7
点赞
8
编组 21备份 2
分享
举报
lawgbk
lawgbk
·
2021-12-30
Like
5 Stocks To Watch For December 30, 2021
Four Corners Property Trust, Inc. reported acquisition of three Mr. Tire Properties for $2.5 million
5 Stocks To Watch For December 30, 2021
看
927
回复
2
点赞
7
编组 21备份 2
分享
举报
lawgbk
lawgbk
·
2021-12-29
Like
Pop Culture Group Stock Jumped 22% in Premarket Trading
Pop Culture Group stock jumped 22% in premarket trading.The stock soared nearly 36% yesterday.
Pop Culture Group Stock Jumped 22% in Premarket Trading
看
1,150
回复
1
点赞
5
编组 21备份 2
分享
举报
lawgbk
lawgbk
·
2021-12-28
Like
Toplines Before US Market Open on Tuesday
The S&P 500 and Dow futures hit all-time highs on Tuesday, building on a record-setting rally amid t
Toplines Before US Market Open on Tuesday
看
1,264
回复
评论
点赞
2
编组 21备份 2
分享
举报
lawgbk
lawgbk
·
2021-12-26
Like
非常抱歉，此主贴已删除
看
1,372
回复
2
点赞
9
编组 21备份 2
分享
举报
lawgbk
lawgbk
·
2021-12-25
Like
非常抱歉，此主贴已删除
看
1,084
回复
2
点赞
5
编组 21备份 2
分享
举报
lawgbk
lawgbk
·
2021-12-24
Ok
非常抱歉，此主贴已删除
看
1,121
回复
评论
点赞
2
编组 21备份 2
分享
举报
lawgbk
lawgbk
·
2021-12-23
Like
U.S. adds Merck pill as 2nd easy-to-use drug against COVID-19
U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another ea
U.S. adds Merck pill as 2nd easy-to-use drug against COVID-19
看
1,421
回复
评论
点赞
9
编组 21备份 2
分享
举报
lawgbk
lawgbk
·
2021-12-22
Like
Allakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data
Allakos continues to slide, falls 87.4% premarket following yesterday's announcement that its late-s
Allakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data
看
756
回复
1
点赞
4
编组 21备份 2
分享
举报
lawgbk
lawgbk
·
2021-12-21
Like
非常抱歉，此主贴已删除
看
1,081
回复
1
点赞
4
编组 21备份 2
分享
举报
lawgbk
lawgbk
·
2021-12-20
Like
Mega-cap growth stocks extended their fall from the previous session
Mega-cap growth stocks extended their fall from the previous session, with Apple, Meta Platforms and
Mega-cap growth stocks extended their fall from the previous session
看
1,357
回复
评论
点赞
7
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3569580504698649","uuid":"3569580504698649","gmtCreate":1606487729628,"gmtModify":1614849041940,"name":"lawgbk","pinyin":"lawgbk","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/aed8dcf3ce6c592dffc1e60aa40d85bc","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":43,"headSize":599,"tweetSize":282,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":2,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.03.06","exceedPercentage":"60.03%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.12.10","exceedPercentage":"80.10%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.08.25","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":199370555,"gmtCreate":1620688716977,"gmtModify":1631888931819,"author":{"id":"3569580504698649","authorId":"3569580504698649","name":"lawgbk","avatar":"https://static.tigerbbs.com/aed8dcf3ce6c592dffc1e60aa40d85bc","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569580504698649","authorIdStr":"3569580504698649"},"themes":[],"htmlText":"Comment pls","listText":"Comment pls","text":"Comment pls","images":[],"top":2,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":7,"repostSize":0,"link":"https://laohu8.com/post/199370555","repostId":"1167387222","repostType":4,"repost":{"id":"1167387222","kind":"news","pubTimestamp":1620657963,"share":"https://www.laohunote.com/m/news/1167387222?lang=&edition=full","pubTime":"2021-05-10 22:46","market":"us","language":"en","title":"Palantir Technologies Could Have an Unpleasant Surprise on This Week’s Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=1167387222","media":"InvestorPlace","summary":"PLTR stock is struggling into a suddenly key earnings report.There are two reasons why first-quarter","content":"<blockquote>PLTR stock is struggling into a suddenly key earnings report.</blockquote><p>There are two reasons why first-quarter earnings on Tuesday look key for<b>Palantir Technologies</b>(NYSE:<b><u>PLTR</u></b>) stock.</p><p>The first is that PLTR is sliding into the report. After being one of the beneficiaries of the “Reddit rally” along with<b>GameStop</b>(NYSE:<b><u>GME</u></b>) and<b>AMC Entertainment</b>(NYSE:<b><u>AMC</u></b>) in late January, PLTR has been nearly halved from its closing high.</p><p>Shares in fact are down more than 15% year-to-date and threatening to hit their lowest levels since November.</p><p>From that perspective, Palantir simply needs to give investors some good news on Tuesday — any kind of good news.</p><p>But the second is that Palantir still is relatively new to the public markets. The company onlyexecuted its direct listingat the end of September. Tuesday’s earnings release is just the company’s third so far.</p><p>Obviously, investors knew of Palantir before it went public. The prospectus filed with the direct listing included historical financial data.</p><p>Still, there are big questions that still surround Palantir — including exactly what kind of company this is. As investors review the Q1 numbers and listen to the post-earnings conference call, they’re going to have those questions in mind — and they’ll be looking for answers.</p><p><b>A Software Company or a Consulting Firm?</b></p><p>There’s one core question that is paramount for PLTR stock. Is Palantir a software company or a consulting firm?</p><p>It’s too simplistic to say that PLTR is too cheap if it’s the former and too expensive if it’s the latter, but there is some truth to that argument. Even after a pullback, and even backing out net cash, PLTR still trades for about 25x this year’s consensus revenue estimate.</p><p>That’s a software multiple, pure and simple. In fact, it’s a somewhat high software multiple. Companies in that ballpark include<b>Snowflake</b>(NYSE:<b><u>SNOW</u></b>),<b>Datadog</b>(NASDAQ:<b><u>DDOG</u></b>), and<b>CrowdStrike</b>(NASDAQ:<b><u>CRWD</u></b>)</p><p>It might seem ridiculous to question the operating model this way 18 years after the company’s founding, and obviously, Palantir does offer software. Most notably, its Foundry platform is the key to its go-to-market strategy going forward.</p><p>But the question is to what extent human intervention is needed to make the Big Data platform work. As<i>New York</i>magazine put it inan intriguing profileof Palantir last year:</p><blockquote>Palantir, it turns out, has run headlong into the problem plaguing many tech firms engaged in the quest for total information awareness: Real-world data is often too messy and complex for computers to translate without lots of help from humans.</blockquote><p>One quick-and-dirty way to answer this question is to look at gross margins. Not coincidentally, for Palantir they’ve been all over the place.</p><p>In 2020, excluding stock-based compensation (which was inflated by the direct listing), gross margins were 80.5%. The year before, they came in at just 71.1%.</p><p>Gross margins thus are going to be a point of focus in Q1. Another 80%-plus print would suggest that Foundry is doing what Palantir, and PLTR bulls, believe it can: cement Palantir as a top-tier software company. That in turn could lead PLTR stock to be revalued as such.</p><p><b>What Else Can Move PLTR Stock</b></p><p>Of course, investors will be looking at more than just one metric.</p><p>Revenue will be a point of focus. After the fourth quarter, Palantir guided for45% year-over-year growthin Q1. That’s about in line with the 47% increase posted for full-year 2020.</p><p>Historically, most software companies guide conservatively (and as a result post beats relative to Wall Street expectations). So even after the pullback in PLTR stock, Palantir needs to hit 45% at least. It probably takes something closer to 50% to get investors truly excited.</p><p>That said, a big beat or miss is somewhat unlikely. Palantir serves most large-cap companies under large-scale contracts, and the company gave Q1 guidance halfway through the quarter. Its visibility toward quarter-end should have been quite clear.</p><p>That leaves earnings. Analysts are looking for 4 cents per share from Palantir, and here too a beat seems likely. But how Palantir drives a beat will be important (while a miss looks dangerous for PLTR stock).</p><p>Again, gross margins will be key, but the same is true for spending.</p><p>As an analyst noted late last year, Palantir’s operating expensesdeclined in 2020. Again excluding share-based compensation, sales and marketing spend dropped 23%, and research and development 14%. (General and administrative expense did increase 15%.)</p><p>The cut in spending seems strange given Palantir’s strong growth. The novel coronavirus pandemic may have played a role, admittedly. The more normalized environment of the first quarter should give some more color on this front.</p><p>All told, this is not likely to be a quarter where a beat on its own sends PLTR stock higher. Given the number of questions here, “how” might be more important than”how much?”</p><p>Palantir fell about 6% in morning trading.</p><p><img src=\"https://static.tigerbbs.com/7b838f84df5e5493aef59679cbb69aeb\" tg-width=\"789\" tg-height=\"523\"></p><p><i>On the date of publication, Vince Martin did not have (either directly or indirectly) any positions in the securities mentioned in this article.</i></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir Technologies Could Have an Unpleasant Surprise on This Week’s Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir Technologies Could Have an Unpleasant Surprise on This Week’s Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-10 22:46 GMT+8 <a href=https://investorplace.com/2021/05/pltr-stock-unpleasant-surprise-this-weeks-earnings/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>PLTR stock is struggling into a suddenly key earnings report.There are two reasons why first-quarter earnings on Tuesday look key forPalantir Technologies(NYSE:PLTR) stock.The first is that PLTR is ...</p>\n\n<a href=\"https://investorplace.com/2021/05/pltr-stock-unpleasant-surprise-this-weeks-earnings/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2021/05/pltr-stock-unpleasant-surprise-this-weeks-earnings/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167387222","content_text":"PLTR stock is struggling into a suddenly key earnings report.There are two reasons why first-quarter earnings on Tuesday look key forPalantir Technologies(NYSE:PLTR) stock.The first is that PLTR is sliding into the report. After being one of the beneficiaries of the “Reddit rally” along withGameStop(NYSE:GME) andAMC Entertainment(NYSE:AMC) in late January, PLTR has been nearly halved from its closing high.Shares in fact are down more than 15% year-to-date and threatening to hit their lowest levels since November.From that perspective, Palantir simply needs to give investors some good news on Tuesday — any kind of good news.But the second is that Palantir still is relatively new to the public markets. The company onlyexecuted its direct listingat the end of September. Tuesday’s earnings release is just the company’s third so far.Obviously, investors knew of Palantir before it went public. The prospectus filed with the direct listing included historical financial data.Still, there are big questions that still surround Palantir — including exactly what kind of company this is. As investors review the Q1 numbers and listen to the post-earnings conference call, they’re going to have those questions in mind — and they’ll be looking for answers.A Software Company or a Consulting Firm?There’s one core question that is paramount for PLTR stock. Is Palantir a software company or a consulting firm?It’s too simplistic to say that PLTR is too cheap if it’s the former and too expensive if it’s the latter, but there is some truth to that argument. Even after a pullback, and even backing out net cash, PLTR still trades for about 25x this year’s consensus revenue estimate.That’s a software multiple, pure and simple. In fact, it’s a somewhat high software multiple. Companies in that ballpark includeSnowflake(NYSE:SNOW),Datadog(NASDAQ:DDOG), andCrowdStrike(NASDAQ:CRWD)It might seem ridiculous to question the operating model this way 18 years after the company’s founding, and obviously, Palantir does offer software. Most notably, its Foundry platform is the key to its go-to-market strategy going forward.But the question is to what extent human intervention is needed to make the Big Data platform work. AsNew Yorkmagazine put it inan intriguing profileof Palantir last year:Palantir, it turns out, has run headlong into the problem plaguing many tech firms engaged in the quest for total information awareness: Real-world data is often too messy and complex for computers to translate without lots of help from humans.One quick-and-dirty way to answer this question is to look at gross margins. Not coincidentally, for Palantir they’ve been all over the place.In 2020, excluding stock-based compensation (which was inflated by the direct listing), gross margins were 80.5%. The year before, they came in at just 71.1%.Gross margins thus are going to be a point of focus in Q1. Another 80%-plus print would suggest that Foundry is doing what Palantir, and PLTR bulls, believe it can: cement Palantir as a top-tier software company. That in turn could lead PLTR stock to be revalued as such.What Else Can Move PLTR StockOf course, investors will be looking at more than just one metric.Revenue will be a point of focus. After the fourth quarter, Palantir guided for45% year-over-year growthin Q1. That’s about in line with the 47% increase posted for full-year 2020.Historically, most software companies guide conservatively (and as a result post beats relative to Wall Street expectations). So even after the pullback in PLTR stock, Palantir needs to hit 45% at least. It probably takes something closer to 50% to get investors truly excited.That said, a big beat or miss is somewhat unlikely. Palantir serves most large-cap companies under large-scale contracts, and the company gave Q1 guidance halfway through the quarter. Its visibility toward quarter-end should have been quite clear.That leaves earnings. Analysts are looking for 4 cents per share from Palantir, and here too a beat seems likely. But how Palantir drives a beat will be important (while a miss looks dangerous for PLTR stock).Again, gross margins will be key, but the same is true for spending.As an analyst noted late last year, Palantir’s operating expensesdeclined in 2020. Again excluding share-based compensation, sales and marketing spend dropped 23%, and research and development 14%. (General and administrative expense did increase 15%.)The cut in spending seems strange given Palantir’s strong growth. The novel coronavirus pandemic may have played a role, admittedly. The more normalized environment of the first quarter should give some more color on this front.All told, this is not likely to be a quarter where a beat on its own sends PLTR stock higher. Given the number of questions here, “how” might be more important than”how much?”Palantir fell about 6% in morning trading.On the date of publication, Vince Martin did not have (either directly or indirectly) any positions in the securities mentioned in this article.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1562,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":692350399,"gmtCreate":1640856657688,"gmtModify":1640856658182,"author":{"id":"3569580504698649","authorId":"3569580504698649","name":"lawgbk","avatar":"https://static.tigerbbs.com/aed8dcf3ce6c592dffc1e60aa40d85bc","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569580504698649","authorIdStr":"3569580504698649"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/692350399","repostId":"1194675549","repostType":4,"repost":{"id":"1194675549","kind":"news","pubTimestamp":1640855408,"share":"https://www.laohunote.com/m/news/1194675549?lang=&edition=full","pubTime":"2021-12-30 17:10","market":"us","language":"en","title":"5 Stocks To Watch For December 30, 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=1194675549","media":"Benzinga","summary":"Four Corners Property Trust, Inc. reported acquisition of three Mr. Tire Properties for $2.5 million","content":"<html><head></head><body><ul><li><b>Four Corners Property Trust, Inc.</b> reported acquisition of three Mr. Tire Properties for $2.5 million. The company acquired Red Robin and AT&T outparcel properties for $2.8 million, and Portillo’s restaurant property for $3.3 million. FCPT shares gained 1.6% to close at $29.69 on Wednesday.</li><li><b>Biogen Inc.</b> shares jumped over 9% on Wednesday after Korea Economic Daily reported that Samsung Group is in talks to buy the company. Biogen shares jumped 9.5% to close at $258.31 on Wednesday, adding another 0.7% in after-hours trading.</li><li><b>VAALCO Energy, Inc.</b> reported the filing of a $50 million shelf registration. VAALCO Energy shares fell 4.5% to $3.2001 in the after-hours trading session.</li></ul><ul><li><b>TPG Pace Beneficial Finance Corp.</b> and EVBox Group have mutually agreed to terminate their earlier announced business combination agreement. TPG Pace Beneficial Finance shares dropped 0.8% to $9.74 in the after-hours trading session.</li><li>Shares of <b>Scienjoy Holding Corporation</b> gained more than 6% on Wednesday as the company agreed to acquire Hongle.tv for $43.8 million. Scienjoy shares rose further by 1.4% to $5.80 in the after-hours trading session.</li></ul></body></html>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Stocks To Watch For December 30, 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Stocks To Watch For December 30, 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-30 17:10 GMT+8 <a href=https://www.benzinga.com/news/earnings/21/12/24825536/5-stocks-to-watch-for-december-30-2021><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Four Corners Property Trust, Inc. reported acquisition of three Mr. Tire Properties for $2.5 million. The company acquired Red Robin and AT&T outparcel properties for $2.8 million, and Portillo’s ...</p>\n\n<a href=\"https://www.benzinga.com/news/earnings/21/12/24825536/5-stocks-to-watch-for-december-30-2021\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/earnings/21/12/24825536/5-stocks-to-watch-for-december-30-2021","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1194675549","content_text":"Four Corners Property Trust, Inc. reported acquisition of three Mr. Tire Properties for $2.5 million. The company acquired Red Robin and AT&T outparcel properties for $2.8 million, and Portillo’s restaurant property for $3.3 million. FCPT shares gained 1.6% to close at $29.69 on Wednesday.Biogen Inc. shares jumped over 9% on Wednesday after Korea Economic Daily reported that Samsung Group is in talks to buy the company. Biogen shares jumped 9.5% to close at $258.31 on Wednesday, adding another 0.7% in after-hours trading.VAALCO Energy, Inc. reported the filing of a $50 million shelf registration. VAALCO Energy shares fell 4.5% to $3.2001 in the after-hours trading session.TPG Pace Beneficial Finance Corp. and EVBox Group have mutually agreed to terminate their earlier announced business combination agreement. TPG Pace Beneficial Finance shares dropped 0.8% to $9.74 in the after-hours trading session.Shares of Scienjoy Holding Corporation gained more than 6% on Wednesday as the company agreed to acquire Hongle.tv for $43.8 million. Scienjoy shares rose further by 1.4% to $5.80 in the after-hours trading session.","news_type":1},"isVote":1,"tweetType":1,"viewCount":927,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696781701,"gmtCreate":1640770110648,"gmtModify":1640770111134,"author":{"id":"3569580504698649","authorId":"3569580504698649","name":"lawgbk","avatar":"https://static.tigerbbs.com/aed8dcf3ce6c592dffc1e60aa40d85bc","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569580504698649","authorIdStr":"3569580504698649"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/696781701","repostId":"1163674351","repostType":4,"repost":{"id":"1163674351","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640769761,"share":"https://www.laohunote.com/m/news/1163674351?lang=&edition=full","pubTime":"2021-12-29 17:22","market":"us","language":"en","title":"Pop Culture Group Stock Jumped 22% in Premarket Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1163674351","media":"Tiger Newspress","summary":"Pop Culture Group stock jumped 22% in premarket trading.The stock soared nearly 36% yesterday.","content":"<html><head></head><body><p>Pop Culture Group stock jumped 22% in premarket trading.The stock soared nearly 36% yesterday.</p><p><img src=\"https://static.tigerbbs.com/bd6f14a690cc0684dca8112f39c885a1\" tg-width=\"842\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pop Culture Group Stock Jumped 22% in Premarket Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPop Culture Group Stock Jumped 22% in Premarket Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-29 17:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Pop Culture Group stock jumped 22% in premarket trading.The stock soared nearly 36% yesterday.</p><p><img src=\"https://static.tigerbbs.com/bd6f14a690cc0684dca8112f39c885a1\" tg-width=\"842\" tg-height=\"621\" referrerpolicy=\"no-referrer\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CPOP":"普普文化"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1163674351","content_text":"Pop Culture Group stock jumped 22% in premarket trading.The stock soared nearly 36% yesterday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1150,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696211586,"gmtCreate":1640701624348,"gmtModify":1640701699103,"author":{"id":"3569580504698649","authorId":"3569580504698649","name":"lawgbk","avatar":"https://static.tigerbbs.com/aed8dcf3ce6c592dffc1e60aa40d85bc","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569580504698649","authorIdStr":"3569580504698649"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696211586","repostId":"1182153918","repostType":4,"repost":{"id":"1182153918","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640696271,"share":"https://www.laohunote.com/m/news/1182153918?lang=&edition=full","pubTime":"2021-12-28 20:57","market":"us","language":"en","title":"Toplines Before US Market Open on Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1182153918","media":"Tiger Newspress","summary":"The S&P 500 and Dow futures hit all-time highs on Tuesday, building on a record-setting rally amid t","content":"<p>The S&P 500 and Dow futures hit all-time highs on Tuesday, building on a record-setting rally amid thin trading volumes, with investors trying to shrug off the impact from Omicron-driven travel disruptions and store closures.</p>\n<p>Apple Inc(AAPL.O) closed all of its 12 New York City stores to indoor shopping, the latest company to tighten protocols as cases surged across the United States and prompted thousands of flight cancellations for the fourth day on Monday.</p>\n<p>However, strong consumer demand trends reinstated confidence about the underlying economic strength and helped Wall Street climb for a fourth straight day on Monday. The S&P 500 and Nasdaq posted their best four-day rally since November 2020.</p>\n<p>Data last week showing the Omicron variant being less deadly than feared, and new pills and more vaccines to fight COVID-19 also spurred risk appetite, putting the three main indexes on pace for monthly gains.</p>\n<p>At 8:00 a.m. ET, Dow e-minis were up 91 points, or 0.25%, S&P 500 e-minis were up 11.75 points, or 0.25%, and Nasdaq 100 e-minis were up 77.75 points, or 0.47%. Some megacap companies have roared in the recent rally, with Apple Inc (AAPL.O) — up marginally in premarket trading — within spitting distance of becoming the first U.S. company to hit $3 trillion in market capitalization.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2529d5fc75126a96cbbc5d6e8f3ec05a\" tg-width=\"667\" tg-height=\"211\" width=\"100%\" height=\"auto\"><span>*Source From Tiger Trade, EST 08:00</span></p>\n<p><b>Stocks making the biggest moves premarket: Apple, Vipshop, Coinbase and others</b></p>\n<p>Apple (AAPL) – The company is once again approaching a $3 trillion market value, needing to reach $182.86 per share to achieve that milestone. Separately, Apple is closing its 12 New York City stores to indoor traffic due to the spread of the Covid-19 omicron variant. Apple edged higher by 0.3% in premarket action.</p>\n<p>Tesla（TSLA）– Tesla has 30% upside in 2022 on China demand, Wedbush Says, and reiterates its outperform rating and $1,400 price target. Tesla stock added 1.77% in premarket.</p>\n<p>Nvidia (NVDA) – The graphics chip maker’s shares added 1.2% in the premarket after rising for the past 4 days in a row and helping to lead the iShares Semiconductor ETF (SOXX) to a record high in Monday trading. Advanced Micro Devices (AMD) – also a big factor in driving the SOXX higher – added 1% in premarket trading. Chip stocks have been rising amid supply shortages and strong demand, leading to higher prices for chips.</p>\n<p>Coinbase (COIN) – The cryptocurrency exchange operator’s shares dropped 2.2% in the premarket as the price of bitcoin retreated, putting the stock in danger of breaking a four-day win streak that saw it gain 17.7% over that stretch.</p>\n<p>Vipshop Holdings (VIPS) – The China-based e-commerce company’s stock fell 2.4% in the premarket after cutting its current-quarter revenue guidance. Vipshop cited its “latest view on the market and operational conditions” without being specific, but a Jefferies report said warmer weather and an increase in Covid-19 cases likely dented consumer demand.</p>\n<p></p>\n<p>R.R. Donnelley (RRD) – R.R. Donnelley slid 1.6% in premarket trading after the business communications and marketing services company disclosed an intrusion into its technical systems. Donnelley said it is investigating and is not aware of any client data being compromised.</p>\n<p></p>\n<p>Extreme Networks (EXTR) – The cloud computing company’s stock jumped 3.6% in premarket action after Needham raised its price target on the stock to $18.50 per share from $16. The stock had closed Monday at $16.03.</p>\n<p></p>\n<p>Howard Hughes (HHC) – The real estate firm has reportedly agreed to sell a controlling interest in the Bank of America Tower in Chicago to private equity firm Oak Hill Advisors for more than $1 billion, according to a Dow Jones report quoting sources familiar with the deal.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Tuesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Tuesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-28 20:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>The S&P 500 and Dow futures hit all-time highs on Tuesday, building on a record-setting rally amid thin trading volumes, with investors trying to shrug off the impact from Omicron-driven travel disruptions and store closures.</p>\n<p>Apple Inc(AAPL.O) closed all of its 12 New York City stores to indoor shopping, the latest company to tighten protocols as cases surged across the United States and prompted thousands of flight cancellations for the fourth day on Monday.</p>\n<p>However, strong consumer demand trends reinstated confidence about the underlying economic strength and helped Wall Street climb for a fourth straight day on Monday. The S&P 500 and Nasdaq posted their best four-day rally since November 2020.</p>\n<p>Data last week showing the Omicron variant being less deadly than feared, and new pills and more vaccines to fight COVID-19 also spurred risk appetite, putting the three main indexes on pace for monthly gains.</p>\n<p>At 8:00 a.m. ET, Dow e-minis were up 91 points, or 0.25%, S&P 500 e-minis were up 11.75 points, or 0.25%, and Nasdaq 100 e-minis were up 77.75 points, or 0.47%. Some megacap companies have roared in the recent rally, with Apple Inc (AAPL.O) — up marginally in premarket trading — within spitting distance of becoming the first U.S. company to hit $3 trillion in market capitalization.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2529d5fc75126a96cbbc5d6e8f3ec05a\" tg-width=\"667\" tg-height=\"211\" width=\"100%\" height=\"auto\"><span>*Source From Tiger Trade, EST 08:00</span></p>\n<p><b>Stocks making the biggest moves premarket: Apple, Vipshop, Coinbase and others</b></p>\n<p>Apple (AAPL) – The company is once again approaching a $3 trillion market value, needing to reach $182.86 per share to achieve that milestone. Separately, Apple is closing its 12 New York City stores to indoor traffic due to the spread of the Covid-19 omicron variant. Apple edged higher by 0.3% in premarket action.</p>\n<p>Tesla（TSLA）– Tesla has 30% upside in 2022 on China demand, Wedbush Says, and reiterates its outperform rating and $1,400 price target. Tesla stock added 1.77% in premarket.</p>\n<p>Nvidia (NVDA) – The graphics chip maker’s shares added 1.2% in the premarket after rising for the past 4 days in a row and helping to lead the iShares Semiconductor ETF (SOXX) to a record high in Monday trading. Advanced Micro Devices (AMD) – also a big factor in driving the SOXX higher – added 1% in premarket trading. Chip stocks have been rising amid supply shortages and strong demand, leading to higher prices for chips.</p>\n<p>Coinbase (COIN) – The cryptocurrency exchange operator’s shares dropped 2.2% in the premarket as the price of bitcoin retreated, putting the stock in danger of breaking a four-day win streak that saw it gain 17.7% over that stretch.</p>\n<p>Vipshop Holdings (VIPS) – The China-based e-commerce company’s stock fell 2.4% in the premarket after cutting its current-quarter revenue guidance. Vipshop cited its “latest view on the market and operational conditions” without being specific, but a Jefferies report said warmer weather and an increase in Covid-19 cases likely dented consumer demand.</p>\n<p></p>\n<p>R.R. Donnelley (RRD) – R.R. Donnelley slid 1.6% in premarket trading after the business communications and marketing services company disclosed an intrusion into its technical systems. Donnelley said it is investigating and is not aware of any client data being compromised.</p>\n<p></p>\n<p>Extreme Networks (EXTR) – The cloud computing company’s stock jumped 3.6% in premarket action after Needham raised its price target on the stock to $18.50 per share from $16. The stock had closed Monday at $16.03.</p>\n<p></p>\n<p>Howard Hughes (HHC) – The real estate firm has reportedly agreed to sell a controlling interest in the Bank of America Tower in Chicago to private equity firm Oak Hill Advisors for more than $1 billion, according to a Dow Jones report quoting sources familiar with the deal.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉",".SPX":"S&P 500 Index","COIN":"Coinbase Global, Inc.","AAPL":"苹果",".DJI":"道琼斯",".IXIC":"NASDAQ Composite","NVDA":"英伟达","AMD":"美国超微公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1182153918","content_text":"The S&P 500 and Dow futures hit all-time highs on Tuesday, building on a record-setting rally amid thin trading volumes, with investors trying to shrug off the impact from Omicron-driven travel disruptions and store closures.\nApple Inc(AAPL.O) closed all of its 12 New York City stores to indoor shopping, the latest company to tighten protocols as cases surged across the United States and prompted thousands of flight cancellations for the fourth day on Monday.\nHowever, strong consumer demand trends reinstated confidence about the underlying economic strength and helped Wall Street climb for a fourth straight day on Monday. The S&P 500 and Nasdaq posted their best four-day rally since November 2020.\nData last week showing the Omicron variant being less deadly than feared, and new pills and more vaccines to fight COVID-19 also spurred risk appetite, putting the three main indexes on pace for monthly gains.\nAt 8:00 a.m. ET, Dow e-minis were up 91 points, or 0.25%, S&P 500 e-minis were up 11.75 points, or 0.25%, and Nasdaq 100 e-minis were up 77.75 points, or 0.47%. Some megacap companies have roared in the recent rally, with Apple Inc (AAPL.O) — up marginally in premarket trading — within spitting distance of becoming the first U.S. company to hit $3 trillion in market capitalization.\n*Source From Tiger Trade, EST 08:00\nStocks making the biggest moves premarket: Apple, Vipshop, Coinbase and others\nApple (AAPL) – The company is once again approaching a $3 trillion market value, needing to reach $182.86 per share to achieve that milestone. Separately, Apple is closing its 12 New York City stores to indoor traffic due to the spread of the Covid-19 omicron variant. Apple edged higher by 0.3% in premarket action.\nTesla（TSLA）– Tesla has 30% upside in 2022 on China demand, Wedbush Says, and reiterates its outperform rating and $1,400 price target. Tesla stock added 1.77% in premarket.\nNvidia (NVDA) – The graphics chip maker’s shares added 1.2% in the premarket after rising for the past 4 days in a row and helping to lead the iShares Semiconductor ETF (SOXX) to a record high in Monday trading. Advanced Micro Devices (AMD) – also a big factor in driving the SOXX higher – added 1% in premarket trading. Chip stocks have been rising amid supply shortages and strong demand, leading to higher prices for chips.\nCoinbase (COIN) – The cryptocurrency exchange operator’s shares dropped 2.2% in the premarket as the price of bitcoin retreated, putting the stock in danger of breaking a four-day win streak that saw it gain 17.7% over that stretch.\nVipshop Holdings (VIPS) – The China-based e-commerce company’s stock fell 2.4% in the premarket after cutting its current-quarter revenue guidance. Vipshop cited its “latest view on the market and operational conditions” without being specific, but a Jefferies report said warmer weather and an increase in Covid-19 cases likely dented consumer demand.\n\nR.R. Donnelley (RRD) – R.R. Donnelley slid 1.6% in premarket trading after the business communications and marketing services company disclosed an intrusion into its technical systems. Donnelley said it is investigating and is not aware of any client data being compromised.\n\nExtreme Networks (EXTR) – The cloud computing company’s stock jumped 3.6% in premarket action after Needham raised its price target on the stock to $18.50 per share from $16. The stock had closed Monday at $16.03.\n\nHoward Hughes (HHC) – The real estate firm has reportedly agreed to sell a controlling interest in the Bank of America Tower in Chicago to private equity firm Oak Hill Advisors for more than $1 billion, according to a Dow Jones report quoting sources familiar with the deal.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1264,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698410261,"gmtCreate":1640489377484,"gmtModify":1640489377962,"author":{"id":"3569580504698649","authorId":"3569580504698649","name":"lawgbk","avatar":"https://static.tigerbbs.com/aed8dcf3ce6c592dffc1e60aa40d85bc","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569580504698649","authorIdStr":"3569580504698649"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/698410261","repostId":"2193178197","repostType":4,"isVote":1,"tweetType":1,"viewCount":1372,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698531768,"gmtCreate":1640441356898,"gmtModify":1640441357348,"author":{"id":"3569580504698649","authorId":"3569580504698649","name":"lawgbk","avatar":"https://static.tigerbbs.com/aed8dcf3ce6c592dffc1e60aa40d85bc","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569580504698649","authorIdStr":"3569580504698649"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/698531768","repostId":"1156159690","repostType":4,"isVote":1,"tweetType":1,"viewCount":1084,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698367005,"gmtCreate":1640307227641,"gmtModify":1640307229602,"author":{"id":"3569580504698649","authorId":"3569580504698649","name":"lawgbk","avatar":"https://static.tigerbbs.com/aed8dcf3ce6c592dffc1e60aa40d85bc","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569580504698649","authorIdStr":"3569580504698649"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698367005","repostId":"2193078140","repostType":4,"isVote":1,"tweetType":1,"viewCount":1121,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698932820,"gmtCreate":1640273258685,"gmtModify":1640273259116,"author":{"id":"3569580504698649","authorId":"3569580504698649","name":"lawgbk","avatar":"https://static.tigerbbs.com/aed8dcf3ce6c592dffc1e60aa40d85bc","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569580504698649","authorIdStr":"3569580504698649"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698932820","repostId":"1192623075","repostType":4,"repost":{"id":"1192623075","kind":"news","pubTimestamp":1640269891,"share":"https://www.laohunote.com/m/news/1192623075?lang=&edition=full","pubTime":"2021-12-23 22:31","market":"us","language":"en","title":"U.S. adds Merck pill as 2nd easy-to-use drug against COVID-19","url":"https://stock-news.laohu8.com/highlight/detail?id=1192623075","media":"SeattleTimes","summary":"U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another ea","content":"<p>U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another easy-to-use medication to battle the rising tide of omicron infections.</p>\n<p>The Food and Drug Administration authorization of Merck’s molnupiravir comes one day after the agency cleared a competing drug from Pfizer. That pill, Paxlovid, is likely to become the first-choice treatment against the virus, thanks to its superior benefits and milder side effects.</p>\n<p>As a result, Merck’s pill is expected to have a smaller role against the pandemic than predicted just a few weeks ago. Its ability to head off severe COVID-19 is much smaller than initially announced and the drug label will warn of serious safety issues, including the potential for birth defects.</p>\n<p>The Food and Drug Administration authorized Merck’s drug for adults with early symptoms of COVID-19 who face the highest risks of hospitalization, including older people and those with conditions like obesity and heart disease. The U.K. first authorized the pill in early November.</p>\n<p>Known as molnupiravir, the Merck drug will carry a warning against use during pregnancy. Women of childbearing age should use birth control during treatment and for a few days after while men should use birth control for at least three months after their final dose, the FDA said.</p>\n<p>The restrictions were expected after an FDA advisory panel only narrowly endorsed the drug last month, warning that its use would have to be strictly tailored to patients who can benefit the most.</p>\n<p>The Pfizer pill works differently and doesn’t carry the same risks. Additionally, Pfizer’s drug was roughly three times more effective in testing, reducing hospitalization and death by nearly 90% among high-risk patients, compared with 30% for Merck’s.</p>\n<p>Some experts question whether there will be much of a role for the Merck drug in the U.S.</p>\n<p>“To the extent that there’s an ample supply of Pfizer’s pill, I think it won’t be used,” said Dr. Gregory Poland of the Mayo Clinic, referring to the Merck drug. “There would be no reason, given it has less efficacy and a higher risk of side effects.”</p>\n<p>For now, the FDA decision provides another potential option against the virus that has killed more than 800,000 Americans, even as health officials brace for record-setting cases, hospitalizations and deaths driven by the omicron variant. Antiviral pills, including Merck’s, are expected to be effective against omicron because they don’t target the spike protein where most of the variant’s worrisome mutations reside.</p>\n<p>The FDA based its decision on results showing nearly 7% of patients taking the drug ended up in the hospital and one died at the end of 30 days. That compared with 10% of patients hospitalized who were taking the placebo and nine deaths.</p>\n<p>Federal officials have agreed to purchase enough of the drug to treat 3.1 million people.</p>\n<p>The U.S. will pay about $700 for each course of Merck’s drug, which requires patients to take four pills twice a day for five days. A review by Harvard University and King’s College London estimated it costs about $18 to make each 40-pill course of treatment.</p>\n<p>Merck’s drug inserts tiny errors into the coronavirus’ genetic code to slow its reproduction. That genetic effect has raised concerns that the drug could cause mutations in human fetuses and even spur more virulent strains of the virus. But FDA scientists said the variant risk is largely theoretical because people take the drug for such a short period of time.</p>","source":"lsy1640271591192","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. adds Merck pill as 2nd easy-to-use drug against COVID-19</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. adds Merck pill as 2nd easy-to-use drug against COVID-19\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-23 22:31 GMT+8 <a href=https://www.seattletimes.com/business/us-adds-merck-pill-as-2nd-easy-to-use-drug-against-covid-19/><strong>SeattleTimes</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another easy-to-use medication to battle the rising tide of omicron infections.\nThe Food and Drug ...</p>\n\n<a href=\"https://www.seattletimes.com/business/us-adds-merck-pill-as-2nd-easy-to-use-drug-against-covid-19/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东","PFE":"辉瑞"},"source_url":"https://www.seattletimes.com/business/us-adds-merck-pill-as-2nd-easy-to-use-drug-against-covid-19/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192623075","content_text":"U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another easy-to-use medication to battle the rising tide of omicron infections.\nThe Food and Drug Administration authorization of Merck’s molnupiravir comes one day after the agency cleared a competing drug from Pfizer. That pill, Paxlovid, is likely to become the first-choice treatment against the virus, thanks to its superior benefits and milder side effects.\nAs a result, Merck’s pill is expected to have a smaller role against the pandemic than predicted just a few weeks ago. Its ability to head off severe COVID-19 is much smaller than initially announced and the drug label will warn of serious safety issues, including the potential for birth defects.\nThe Food and Drug Administration authorized Merck’s drug for adults with early symptoms of COVID-19 who face the highest risks of hospitalization, including older people and those with conditions like obesity and heart disease. The U.K. first authorized the pill in early November.\nKnown as molnupiravir, the Merck drug will carry a warning against use during pregnancy. Women of childbearing age should use birth control during treatment and for a few days after while men should use birth control for at least three months after their final dose, the FDA said.\nThe restrictions were expected after an FDA advisory panel only narrowly endorsed the drug last month, warning that its use would have to be strictly tailored to patients who can benefit the most.\nThe Pfizer pill works differently and doesn’t carry the same risks. Additionally, Pfizer’s drug was roughly three times more effective in testing, reducing hospitalization and death by nearly 90% among high-risk patients, compared with 30% for Merck’s.\nSome experts question whether there will be much of a role for the Merck drug in the U.S.\n“To the extent that there’s an ample supply of Pfizer’s pill, I think it won’t be used,” said Dr. Gregory Poland of the Mayo Clinic, referring to the Merck drug. “There would be no reason, given it has less efficacy and a higher risk of side effects.”\nFor now, the FDA decision provides another potential option against the virus that has killed more than 800,000 Americans, even as health officials brace for record-setting cases, hospitalizations and deaths driven by the omicron variant. Antiviral pills, including Merck’s, are expected to be effective against omicron because they don’t target the spike protein where most of the variant’s worrisome mutations reside.\nThe FDA based its decision on results showing nearly 7% of patients taking the drug ended up in the hospital and one died at the end of 30 days. That compared with 10% of patients hospitalized who were taking the placebo and nine deaths.\nFederal officials have agreed to purchase enough of the drug to treat 3.1 million people.\nThe U.S. will pay about $700 for each course of Merck’s drug, which requires patients to take four pills twice a day for five days. A review by Harvard University and King’s College London estimated it costs about $18 to make each 40-pill course of treatment.\nMerck’s drug inserts tiny errors into the coronavirus’ genetic code to slow its reproduction. That genetic effect has raised concerns that the drug could cause mutations in human fetuses and even spur more virulent strains of the virus. But FDA scientists said the variant risk is largely theoretical because people take the drug for such a short period of time.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1421,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691616001,"gmtCreate":1640182784825,"gmtModify":1640183347066,"author":{"id":"3569580504698649","authorId":"3569580504698649","name":"lawgbk","avatar":"https://static.tigerbbs.com/aed8dcf3ce6c592dffc1e60aa40d85bc","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569580504698649","authorIdStr":"3569580504698649"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691616001","repostId":"1163953446","repostType":4,"repost":{"id":"1163953446","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640182473,"share":"https://www.laohunote.com/m/news/1163953446?lang=&edition=full","pubTime":"2021-12-22 22:14","market":"us","language":"en","title":"Allakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data","url":"https://stock-news.laohu8.com/highlight/detail?id=1163953446","media":"Tiger Newspress","summary":"Allakos continues to slide, falls 87.4% premarket following yesterday's announcement that its late-s","content":"<p>Allakos continues to slide, falls 87.4% premarket following yesterday's announcement that its late-stage studies, KRYPTOS and ENIGMA 2failed to achieve statistical significance.</p>\n<p><img src=\"https://static.tigerbbs.com/961eae374dfe4dd479394caaf470012c\" tg-width=\"714\" tg-height=\"590\" width=\"100%\" height=\"auto\"></p>\n<p>The studies met their histologic co-primary endpoints but failed to achieve symptomatic endpoints.</p>\n<p>In ENIGMA, patients treated with lirentelimab achieved a 10.0-point reduction in Total Symptom Score-6 (TSS-6) at weeks 23-24 from baseline (baseline = 29.5) compared to an 11.5-point reduction in the placebo group (baseline = 27.7; p=0.343).</p>\n<p>On the second co-primary endpoint of absolute mean change in patient reported Dysphagia Symptom Questionnaire in KRYPTOS trial, the high-dose group achieved a 17.4-point reduction, the low-dose group achieved an 11.9-point reduction and placebo achieved a 14.6-point reduction.</p>\n<p>Following this disappointing result, several analysts lowered their ratings of the stock and slashed the price targets.</p>\n<p>William Blair downgraded the stock to Market Perform from Outperform.</p>\n<p>Analysts of the firm say, \"while we believe lirentelimab has shown clear evidence of histologic activity against eosinophils and mast cells, the failure to achieve co-primary endpoints of patient reported symptoms in both studies raises questions about whether these histologic improvements can translate into clinical improvements.\"</p>\n<p>With lirentelimab performing worse than placebo, there are clearly questions as to why the clean results in Phase II didn’t translate, the analyst notes.</p>\n<p>Cowen analyst Joseph Thome has also cut the recommendation on Allakos to Market Perform from Outperform without the price target (PT) pending pipeline clarity.</p>\n<p>SVB Leerink analyst Thomas Smith downgraded the stock to Market Perform from Outperform, with PT of $17.</p>\n<p>Barclays analyst Carter Gould lowered the firm's PT on Allakos to $8 from $36 and keeps an Underweight rating. The company's lead asset failed in key Phase 3 studies, Gould tells investors in a research note. He views this as the \"end game\" for lirentelimab.</p>\n<p>Morgan Stanley says Allakos' disappointing data increase eosinophilic gastrointestinal diseases (EGIDs) uncertainty.</p>\n<p>Jefferies analyst Maury Raycroft cut the recommendation on Allakos to Hold from Buy.</p>\n<p>LifeSci Capital analyst Samuel Slutsky downgraded the stock to Market Perform from Outperform.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Allakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAllakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-22 22:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Allakos continues to slide, falls 87.4% premarket following yesterday's announcement that its late-stage studies, KRYPTOS and ENIGMA 2failed to achieve statistical significance.</p>\n<p><img src=\"https://static.tigerbbs.com/961eae374dfe4dd479394caaf470012c\" tg-width=\"714\" tg-height=\"590\" width=\"100%\" height=\"auto\"></p>\n<p>The studies met their histologic co-primary endpoints but failed to achieve symptomatic endpoints.</p>\n<p>In ENIGMA, patients treated with lirentelimab achieved a 10.0-point reduction in Total Symptom Score-6 (TSS-6) at weeks 23-24 from baseline (baseline = 29.5) compared to an 11.5-point reduction in the placebo group (baseline = 27.7; p=0.343).</p>\n<p>On the second co-primary endpoint of absolute mean change in patient reported Dysphagia Symptom Questionnaire in KRYPTOS trial, the high-dose group achieved a 17.4-point reduction, the low-dose group achieved an 11.9-point reduction and placebo achieved a 14.6-point reduction.</p>\n<p>Following this disappointing result, several analysts lowered their ratings of the stock and slashed the price targets.</p>\n<p>William Blair downgraded the stock to Market Perform from Outperform.</p>\n<p>Analysts of the firm say, \"while we believe lirentelimab has shown clear evidence of histologic activity against eosinophils and mast cells, the failure to achieve co-primary endpoints of patient reported symptoms in both studies raises questions about whether these histologic improvements can translate into clinical improvements.\"</p>\n<p>With lirentelimab performing worse than placebo, there are clearly questions as to why the clean results in Phase II didn’t translate, the analyst notes.</p>\n<p>Cowen analyst Joseph Thome has also cut the recommendation on Allakos to Market Perform from Outperform without the price target (PT) pending pipeline clarity.</p>\n<p>SVB Leerink analyst Thomas Smith downgraded the stock to Market Perform from Outperform, with PT of $17.</p>\n<p>Barclays analyst Carter Gould lowered the firm's PT on Allakos to $8 from $36 and keeps an Underweight rating. The company's lead asset failed in key Phase 3 studies, Gould tells investors in a research note. He views this as the \"end game\" for lirentelimab.</p>\n<p>Morgan Stanley says Allakos' disappointing data increase eosinophilic gastrointestinal diseases (EGIDs) uncertainty.</p>\n<p>Jefferies analyst Maury Raycroft cut the recommendation on Allakos to Hold from Buy.</p>\n<p>LifeSci Capital analyst Samuel Slutsky downgraded the stock to Market Perform from Outperform.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALLK":"Allakos Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1163953446","content_text":"Allakos continues to slide, falls 87.4% premarket following yesterday's announcement that its late-stage studies, KRYPTOS and ENIGMA 2failed to achieve statistical significance.\n\nThe studies met their histologic co-primary endpoints but failed to achieve symptomatic endpoints.\nIn ENIGMA, patients treated with lirentelimab achieved a 10.0-point reduction in Total Symptom Score-6 (TSS-6) at weeks 23-24 from baseline (baseline = 29.5) compared to an 11.5-point reduction in the placebo group (baseline = 27.7; p=0.343).\nOn the second co-primary endpoint of absolute mean change in patient reported Dysphagia Symptom Questionnaire in KRYPTOS trial, the high-dose group achieved a 17.4-point reduction, the low-dose group achieved an 11.9-point reduction and placebo achieved a 14.6-point reduction.\nFollowing this disappointing result, several analysts lowered their ratings of the stock and slashed the price targets.\nWilliam Blair downgraded the stock to Market Perform from Outperform.\nAnalysts of the firm say, \"while we believe lirentelimab has shown clear evidence of histologic activity against eosinophils and mast cells, the failure to achieve co-primary endpoints of patient reported symptoms in both studies raises questions about whether these histologic improvements can translate into clinical improvements.\"\nWith lirentelimab performing worse than placebo, there are clearly questions as to why the clean results in Phase II didn’t translate, the analyst notes.\nCowen analyst Joseph Thome has also cut the recommendation on Allakos to Market Perform from Outperform without the price target (PT) pending pipeline clarity.\nSVB Leerink analyst Thomas Smith downgraded the stock to Market Perform from Outperform, with PT of $17.\nBarclays analyst Carter Gould lowered the firm's PT on Allakos to $8 from $36 and keeps an Underweight rating. The company's lead asset failed in key Phase 3 studies, Gould tells investors in a research note. He views this as the \"end game\" for lirentelimab.\nMorgan Stanley says Allakos' disappointing data increase eosinophilic gastrointestinal diseases (EGIDs) uncertainty.\nJefferies analyst Maury Raycroft cut the recommendation on Allakos to Hold from Buy.\nLifeSci Capital analyst Samuel Slutsky downgraded the stock to Market Perform from Outperform.","news_type":1},"isVote":1,"tweetType":1,"viewCount":756,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691020559,"gmtCreate":1640099586062,"gmtModify":1640099586537,"author":{"id":"3569580504698649","authorId":"3569580504698649","name":"lawgbk","avatar":"https://static.tigerbbs.com/aed8dcf3ce6c592dffc1e60aa40d85bc","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569580504698649","authorIdStr":"3569580504698649"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691020559","repostId":"2193154031","repostType":4,"isVote":1,"tweetType":1,"viewCount":1081,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693634400,"gmtCreate":1640012111093,"gmtModify":1640012111573,"author":{"id":"3569580504698649","authorId":"3569580504698649","name":"lawgbk","avatar":"https://static.tigerbbs.com/aed8dcf3ce6c592dffc1e60aa40d85bc","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569580504698649","authorIdStr":"3569580504698649"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693634400","repostId":"1115322314","repostType":4,"repost":{"id":"1115322314","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640011665,"share":"https://www.laohunote.com/m/news/1115322314?lang=&edition=full","pubTime":"2021-12-20 22:47","market":"us","language":"en","title":"Mega-cap growth stocks extended their fall from the previous session","url":"https://stock-news.laohu8.com/highlight/detail?id=1115322314","media":"Tiger Newspress","summary":"Mega-cap growth stocks extended their fall from the previous session, with Apple, Meta Platforms and","content":"<p>Mega-cap growth stocks extended their fall from the previous session, with Apple, Meta Platforms and Microsoft Corp down between 1% and 3%.</p>\n<p><img src=\"https://static.tigerbbs.com/bcbe2eb85bd02485d4f915039e5a7c33\" tg-width=\"709\" tg-height=\"607\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mega-cap growth stocks extended their fall from the previous session</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMega-cap growth stocks extended their fall from the previous session\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-20 22:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Mega-cap growth stocks extended their fall from the previous session, with Apple, Meta Platforms and Microsoft Corp down between 1% and 3%.</p>\n<p><img src=\"https://static.tigerbbs.com/bcbe2eb85bd02485d4f915039e5a7c33\" tg-width=\"709\" tg-height=\"607\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1115322314","content_text":"Mega-cap growth stocks extended their fall from the previous session, with Apple, Meta Platforms and Microsoft Corp down between 1% and 3%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1357,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}